Haemonetics (NYSE:HAE) Stock Price Up 2.2%

Haemonetics Co. (NYSE:HAE)’s stock price rose 2.2% during mid-day trading on Wednesday . The stock traded as high as $95.77 and last traded at $97.62, approximately 29,335 shares were traded during trading. A decline of 96% from the average daily volume of 677,800 shares. The stock had previously closed at $95.54.

HAE has been the subject of several research analyst reports. Raymond James lifted their price objective on Haemonetics from $145.00 to $150.00 and gave the company an “outperform” rating in a research note on Wednesday, February 5th. ValuEngine raised Haemonetics from a “sell” rating to a “hold” rating in a research note on Monday, March 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $142.00 price target on shares of Haemonetics in a research note on Tuesday, February 4th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Haemonetics has a consensus rating of “Buy” and an average price target of $144.33.

The stock has a market cap of $4.81 billion, a PE ratio of 68.52, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a fifty day moving average price of $106.44 and a 200 day moving average price of $116.68. The company has a quick ratio of 1.28, a current ratio of 2.27 and a debt-to-equity ratio of 0.54.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.18. The firm had revenue of $259.00 million for the quarter, compared to the consensus estimate of $255.40 million. Haemonetics had a return on equity of 27.78% and a net margin of 7.98%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 earnings per share. As a group, research analysts predict that Haemonetics Co. will post 3.35 earnings per share for the current year.

In related news, SVP Jacqueline Scanlan sold 1,299 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $100.50, for a total transaction of $130,549.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michelle L. Basil sold 395 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $98.00, for a total value of $38,710.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,812 shares of company stock worth $180,824. Company insiders own 1.32% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. increased its holdings in Haemonetics by 9.5% during the 4th quarter. Macquarie Group Ltd. now owns 136,315 shares of the medical instruments supplier’s stock valued at $15,663,000 after purchasing an additional 11,837 shares during the period. Norges Bank bought a new stake in Haemonetics during the 4th quarter valued at approximately $82,965,000. Geode Capital Management LLC boosted its position in Haemonetics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 748,270 shares of the medical instruments supplier’s stock valued at $85,975,000 after acquiring an additional 19,509 shares in the last quarter. Mason Street Advisors LLC boosted its position in Haemonetics by 1.3% during the 4th quarter. Mason Street Advisors LLC now owns 26,958 shares of the medical instruments supplier’s stock valued at $3,097,000 after acquiring an additional 333 shares in the last quarter. Finally, Capital Research Global Investors boosted its position in Haemonetics by 5.6% during the 4th quarter. Capital Research Global Investors now owns 2,694,800 shares of the medical instruments supplier’s stock valued at $309,633,000 after acquiring an additional 143,800 shares in the last quarter. Institutional investors own 99.13% of the company’s stock.

About Haemonetics (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Special Dividends

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.